Amag Pharmaceuticals (AMAG) Gets a Hold Rating from Jefferies


In a report released yesterday, Eun Yang from Jefferies reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $22. The company’s shares closed yesterday at $23.20.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.1% and a 51.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Array Biopharma.

Currently, the analyst consensus on Amag Pharmaceuticals is a Hold with an average price target of $23.40, representing a 0.9% upside. In a report released yesterday, Piper Jaffray also maintained a Hold rating on the stock with a $22 price target.

.

See today’s analyst top recommended stocks >>

Based on Amag Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.08 million. In comparison, last year the company had a GAAP net loss of $14.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts